SCHEMBL17199124

SCHEMBL17199124

Nc1ccc2[nH]c(-c3ccc(F)cc3)cc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.60
MAPT P10636 4/20 0.49
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
KDM4E B2RXH2 3/20 0.49
MEN1 O00255 3/20 0.49
ALDH1A1 P00352 3/20 0.49
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
HPGD P15428 2/20 0.49
GFER P55789 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CYP2A6 P11509 1/20 0.49
KEAP1 Q14145 1/20 0.49
HPN P05981 1/20 0.46
GCGR P47871 1/20 0.46
MAPK14 Q16539 1/20 0.46
KIT P10721 1/20 0.46
PDE10A Q9Y233 1/20 0.44
CTSV O60911 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29513520 0.91 CYP2A6 (0.57) CYP1A1MAPTNPC1RAB9AKDM4E
SCHEMBL1663580 0.89 CYP2A6 (0.55) CYP1A1MAPTNPC1RAB9AKDM4E
SCHEMBL30869753 0.85 CYP1A1 (0.68) CYP1A1MAPTNPC1RAB9AKDM4E
SCHEMBL28230938 0.83 RAB9A (0.65) CYP1A1MAPTNPC1RAB9AKDM4E
SCHEMBL17199123 0.83 PDE10A (0.63) CYP1A1MAPTNPC1RAB9AKDM4E
SCHEMBL31548558 0.82 NPC1 (0.64) CYP1A1MAPTNPC1RAB9AKDM4E
SCHEMBL1465037 0.82 NPC1 (0.64) CYP1A1MAPTNPC1RAB9AKDM4E
SCHEMBL10172983 0.81 CYP2A6 (0.63) CYP1A1MAPTNPC1RAB9AKDM4E
Hydrochloric Acid SCHEMBL11003375 0.81 NPC1 (0.62) CYP1A1MAPTNPC1RAB9AKDM4E
SCHEMBL13577818 0.80 CYP1A1 (0.50) CYP1A1MAPTNPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3133068-B1 AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF Shanghai hengrui pharmaceutical co ltd (CN) 2020-11-25 EP disclosed
EP-3133068-A1 AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) 2017-02-22 EP disclosed
US-20170037044-A1 AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2017-02-09 US disclosed
WO-2015158204-A1 AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF 上海恒瑞医药有限公司 2015-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037044-A1 AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF PTGES, PTGS1, PTGIS CYP1A1 33/4885MAPT 3600/4885NPC1 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.